These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18043578)

  • 21. Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.
    Rice AJ; Steward MA; Quinn CM
    J Clin Pathol; 2002 Dec; 55(12):921-5. PubMed ID: 12461058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
    Martinez AP; Cohen C; Hanley KZ; Li XB
    Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion.
    Wan ZB; Gao HY; Wei L; Zhang AQ; Zhang JY; Wang Y; Wang DD; Zhang Y
    Medicine (Baltimore); 2018 Nov; 97(44):e13055. PubMed ID: 30383678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
    Mack L; Kerkvliet N; Doig G; O'Malley FP
    Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy.
    Ravaioli S; Tumedei MM; Foca F; Maltoni R; Rocca A; Massa I; Pietri E; Bravaccini S
    Int J Exp Pathol; 2017 Oct; 98(5):289-295. PubMed ID: 29193395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. bcl-2 expression in the spectrum of preinvasive breast lesions.
    Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
    Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.
    Bos R; Zhong H; Hanrahan CF; Mommers EC; Semenza GL; Pinedo HM; Abeloff MD; Simons JW; van Diest PJ; van der Wall E
    J Natl Cancer Inst; 2001 Feb; 93(4):309-14. PubMed ID: 11181778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
    Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status.
    Oh YL; Choi JS; Song SY; Ko YH; Han BK; Nam SJ; Yang JH
    Pathol Int; 2001 Feb; 51(2):94-9. PubMed ID: 11169147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
    Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C
    Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen receptor expression in ductal carcinoma in situ of the breast: not a helpful marker for classification such as estrogen receptor alpha and progesterone receptor.
    Rody A; Diallo R; Poremba C; Wuelfing P; Kissler S; Solbach C; Kaufmann M; Jackisch C
    Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):25-9. PubMed ID: 15722790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
    Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
    Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
    de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
    Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Relationships between HER2 Overexpression and DCIS Characteristics.
    Di Cesare P; Pavesi L; Villani L; Battaglia A; Da Prada GA; Riccardi A; Frascaroli M
    Breast J; 2017 May; 23(3):307-314. PubMed ID: 27943525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ.
    Aguiar FN; Mendes HN; Cirqueira CS; Bacchi CE; Carvalho FM
    Clinics (Sao Paulo); 2013 May; 68(5):638-43. PubMed ID: 23778411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.
    Ubago JM; Blanco LZ; Shen T; Siziopikou KP
    Am J Clin Pathol; 2019 Jul; 152(2):169-176. PubMed ID: 30984969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
    Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S
    Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.